Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163617 · ClinicalTrials.gov registry record · Phase 2
The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01163617 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 85 participants.
The verdict
NCT01163617, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This was an open-label, Phase 2 study designed to obtain user experience data (Phase A) and injection time data (Phase B) in experienced adalimumab patients injected with the Physiolis pre-filled syringe and autoinjector used to administer adalimumab.
Interventions
- DEVICE Adalimumab delivered in current syringe
- DEVICE Adalimumab delivered in Physiolis syringe
- DEVICE Adalimumab delivered in current autoinjector
- DEVICE Adalimumab delivered in Physiolis autoinjector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163617
The ClinicalTrials.gov registry entry for NCT01163617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab delivered in current syringe is the first listed.
NCT01163617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163617 about?
NCT01163617 is a clinical study titled "The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients". This was an open-label, Phase 2 study designed to obtain user experience data (Phase A) and injection time data (Phase B) in experienced adalimumab patients injected with the Physiolis pre-filled syringe and autoinjector used to administer adalimumab.
What is the current status of trial NCT01163617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01163617?
The interventions under investigation include: Adalimumab delivered in current syringe (DEVICE), Adalimumab delivered in Physiolis syringe (DEVICE), Adalimumab delivered in current autoinjector (DEVICE), Adalimumab delivered in Physiolis autoinjector (DEVICE).
Who is sponsoring clinical trial NCT01163617?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.